In this free webinar, review and understand the transformative impact of a biomarker-driven approach to identify sub-populations in clinical trials. Attendees will discover how artificial intelligence (AI) can expedite the analysis of clinical data sets and identify promising patient sub-populations for more focused trial design, optimization, rescue and benchmarking. The featured speakers will share the experience of AI in action with IQVIA’s SOMS solution.

TORONTO, April 18, 2024 /PRNewswire-PRWeb/ — It is no secret that the cost to bring a drug to market has increased and failed trials can cost sponsors upwards of a billion dollars. Statistics have shown that up to 65 percent of Phase II and over 35 percent of Phase III clinical trials do not progress to the next stage. This results in approximately 12 percent of clinical trials resulting in therapies approved by the US Food and Drug Administration (FDA).

Failed trials often have sub-populations of patients who respond well to the treatment being evaluated; however, the trial is abandoned because of the overall data. This results in a financial loss for sponsors and missed opportunity for patients to benefit from a therapeutic innovation. Moreover, the process of executing this analysis requires a resource-intensive, manual process.

Artificial intelligence (AI), enabled via technology platforms, is a key driver of change in the clinical trial industry. This webinar will delve into how AI, through a SaaS platform like IQVIA’s Sub-Population Optimization and Modeling Solution (SOMS), can rapidly analyze clinical data sets to identify promising patient sub-groups that could benefit from a therapy, thereby increasing safety and treatment outcomes.

SOMS uses an industry method called subgroup identification based on differential effect search (SIDES), which is validated, published and defendable to health authorities. By leveraging SIDES, sub-populations can be identified as fast as 30 seconds (up to 99 percent-time savings over current, manual biostatistics-based processes).

Harnessing the power of SIDES in a technology platform enables sponsors to:

•     Identify predictive biomarkers and sub-populations
•     Track sub-populations
•     Design and adjust strategies to maximize trial success
•     Develop rescue strategies for poorly performing trials
•     Execute trial simulation and benchmarking

Register for this webinar to learn how IQVIA’s SOMS is leveraging AI for biomarker-driven sub-population optimization to help conduct clinical trials.

Join experts from IQVIA Technologies, Adrian Kizewski, Associate Director, Clinical Technology; and Naouel Baili, Director, AI Scientist, for the live webinar on Tuesday, May 7, 2024, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Strategies for Biomarker-Driven Sub-population Optimization in Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com

View original content to download multimedia:https://www.prweb.com/releases/strategies-for-biomarker-driven-sub-population-optimization-in-clinical-trials-upcoming-webinar-hosted-by-xtalks-302120024.html

SOURCE Xtalks